Wednesday, 18 February 2015

ScHARRNews - Saturday February 14th - Wednesday February 18th 2015



New project: Assessing the cost-effectiveness of including Adrenoleukodystrophy (ALD) in the newborn blood spot screening programme
The charity ALD Life has commissioned researcher in HEDS to assess the cost-effectiveness of including ALD in the NHS Newborn Blood Spot Screening Programme. ALD is a rare inherited metabolic disease that is estimated to affect 1 in 20,000 males. It affects the nervous system and adrenal glands and can lead to progressive neurological disability and death. Studies have shown stem cell transplantat
Report published in NIHR Journals Library. Secondary Analysis and Literature Review of Community Rehabilitation and Intermediate Care: an Information Resource
This research was led by Professor Pamela Enderby and DrSteven Ariss (ScHARR, RAT Group), and was based on a reanalysis of a merged data set from two previous intermediate care (IC) projects in order to identify patient characteristics associated with outcomes. The combined data set contained data on 8070 patient admissions, from 32 IC teams across England and included details of the service cont


World's most highly cited researchers
Highly Cited Researchers 2014 represents some of world’s leading scientific minds. Over three thousand researchers earned the distinction by writing the greatest numbers of reports officially designated by Essential Science Indicators as Highly Cited Papers -ranking among the top 1% most cited for their subject field and year of publication, earning them the mark of exceptional impact.And John Bra
Multimorbidities in older people research call
The NIHR will be launching a themed call for research on multimorbidities in older people on 25th February. To find out more click here.

FEB 16

TElehealth in CHronic disease: Mixed-methods study to develop the TECH conceptual model for intervention design and evaluation
Author(s):Salisbury, C. | Thomas, C. | O'Cathain, A. | Rogers, A. | Pope, C. | Yardley, L. | Hollinghurst, S. | Fahey, T. | Lewis, G. | Large, S. | Edwards, L. | Rowsell, A. | Segar, J. | Brownsell, S. | Montgomery, A.A.Publication year: 2015Journal / Book title: BMJ OpenAccess all results for your search in Scopus
New ovarian cancer drug one step closer
Ovarian cancer patients throughout Europe and the United States could soon be treated with a new drug discovered through pioneering research at the University of Sheffield funded by Yorkshire Cancer Research.
Peer review is fraught with problems, and we need a fix
By Andy Tattersall, University of Sheffield Dirty Harry once said, “Opinions are like assholes; everybody has one”. Now that the internet has made it easier than ever to share an unsolicited opinion, traditional methods of academic review are beginning to show their age. We can now leave a public comment on just about anything – including the news, politics, YouTube videos, this article and even
New project: Cost-effectiveness of screening for ovarian cancer
Researchers in HEDS have been commissioned by Public Health England to evaluate the cost-effectiveness of screening for ovarian cancer. Ovarian cancer is the leading cause of death from gynaecological cancers in the United Kingdom, with the majority of women being diagnosed with late-stage cancer. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) has enrolled over 200,00
JPND fact sheets - available to download now!
The Joint Programme of Neurodegenerative Disease Research (JPND) have finalised 10 fact sheets for the 10 JPND-supported working groups funded under the 2014 JPND call onfor WGs on Longitudinal cohort studies.Individual PDF versions of these fact sheets are available to download on the JPND website.You can also sign up to the JPND news email alerts by clicking here.

No comments:

Post a Comment